From powder to implant

Quality assurance for additively manufactured implants.

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

CAR-T-terapin Carvykti rekommenderas i Sverige – behandling förbereds

Karolinska universitetssjukhuset har för första gången i Sverige inlett förberedelser för att behandla en patient med blodcancerformen multipelt myelom med CAR-...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

An easy way to handle microtiter plate stacks

Do you want to automate handling of microtiter plates.? Have a look at a very simple solution on how to handle them.

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...

Abbvie i miljardaffär – tar sikte på in vivo CAR-T

Abbvie har tecknat avtal om att förvärva det kliniska biotechbolaget Capstan Therapeutics för upp till 2,1 miljarder dollar och får därmed tillgång till bland a...

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

Bayer has cut 1,500 roles – so far

German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Bakslag i USA får Elicera att ändra patentstrategi

Car T-bolaget Elicera har fått avslag på en patentansökan i USA för sin Itank-plattform – men uppger sig nu ha tagit fram en ny strategi för att ändå nå patentskydd.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Allogene avvecklar experimentell antikropp efter dödsfall

Det amerikanska bioteknikbolaget Allogene Therapeutics stoppar helt användningen av sin experimentella antikropp ALLO-647 efter ett dödsfall i bolagets avgörande CAR-T-studie.

Swedish team tests Alzheimer antibody for brain imaging

Recent breakthroughs in Alzheimer’s treatment have increased the need for precise diagnostics in the field. Researchers in Uppsala are working to develop improv...

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pivotal CAR-T trial....

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

QPS Netherlands B.V